X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide delays metastasis in men with non-metastatic castration̶resistant prostate cancer (CRPC) without worsening health-related quality of life (HRQoL) and significantly decreases the... Read More

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

New findings support the safety of including selected men with Gleason 3+4 prostate cancer in active surveillance (AS) programs, Australian researchers reported... Read More

Diet and Dosage: How Much Could Patients Save?

The authors of a recent prostate cancer study claim that a drug manufacturer and the US Food and Drug Administration... Read More

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

The Prostate Cancer Prevention Trial (PCPT) showed that the use of finasteride, a 5-alpha-reductase inhibitor, for 7 years reduced the... Read More

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

Adding mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy (ADT) does not improve overall survival (OS) or disease-free survival (DFS)... Read More

Circulating Tumor Cell Count May Predict for Overall Survival in Prostate Cancer

Circulating tumor cell (CTC) counts correspond with overall survival (OS) among patients with early-phase metastatic castration-resistant prostate cancer (mCRPC), according to a study... Read More

The Potential of Radium-223 in Modern Prostate Cancer Treatment

The majority of patients with metastatic castration-resistant prostate cancer (CRPC) have evidence of bone metastases. Among available bone-targeted therapies, only radium-223 dichloride... Read More

Enzalutamide May Not Affect Seizure Incidence Among Men With Prostate Cancer, Seizure Risk Factors

Enzalutamide may not increase the incidence of seizure among patients with metastatic castration-resistant prostate cancer (mCRPC) and seizure risk factors,... Read More

Insurance Status, Race Predict Prostate Cancer Outcomes

Caucasian and African American patients with prostate cancer who are insured privately may have different clinical outcomes, but these disparities are less... Read More

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

Reduced-dose cabazitaxel is non-inferior to the standard dose for patients with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel, according to... Read More

1 2 3 4